<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971200</url>
  </required_header>
  <id_info>
    <org_study_id>2021-04-373</org_study_id>
    <nct_id>NCT04971200</nct_id>
  </id_info>
  <brief_title>Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo</brief_title>
  <acronym>TILDVIT-1227</acronym>
  <official_title>Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Premier Specialists, Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Premier Specialists, Australia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitiligo is a common acquired depigmentation disorder affecting approximately 2% of the world&#xD;
      population. The purpose of this pilot study is to evaluate the effect and the safety of&#xD;
      Tildrakizumab in adult participants with vitiligo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tildrakizumab is a monoclonal antibody against interleukin (IL) 23, specifically&#xD;
      anti-IL23p19. It is approved in the USA, Europe and Australia for psoriasis. The psoriasis&#xD;
      dose is 100mg administered subcutaneously at weeks 0, 4 and every 12 weeks. Recent research&#xD;
      has shown medications used to treat psoriasis may be effective in other immune mediated or&#xD;
      autoimmune diseases such as vitiligo. With studies underway assessing the effect of Janus&#xD;
      Kinase (JAK) inhibitors in psoriasis and vitiligo, this study seeks to determine if an IL-23&#xD;
      inhibitor is beneficial in halting disease progression and inducing repigmentation in&#xD;
      vitiligo. There is some data to indicate that a higher dose of Tildrakizumab is effective for&#xD;
      other autoimmune diseases such as psoriasis and hidradenitis suppurativa. For psoriasis,&#xD;
      200mg dosage was more effective than 100mg dosage. For hidradenitis suppurativa, a dosage of&#xD;
      200mg every 4 weeks was shown to be effective. Patients included in this study will start&#xD;
      Tildrakizumab at a dosage of 200mg every 4 weeks for 6 months. There is a total of 8 visits&#xD;
      involved in this study. Tildrakizumab is provided during visit 2, 3, 4, 5, 6, 7. Visit 1is a&#xD;
      screening visit. At visit 1 and visit 8 no study drug will be provided.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage repigmentation: Vitiligo Area Scoring Index (VASI)</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage repigmentation is assessed through change in score from baseline. Range 0-100. Higher score=greater depigmentation/worse</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage repigmentation: Vitiligo Extent Score (VES)</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage repigmentation is assessed through change in score from baseline. Range 0-100. Higher score=greater depigmentation/worse</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage repigmentation: Photographs</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage repigmentation is assessed through comparison of photographs of vitiligo lesions from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage repigmentation: Vitiligo Area Scoring Index (VASI)</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage repigmentation is assessed through change in score from baseline. Range 0-100. Higher score=greater depigmentation/worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage repigmentation: Vitiligo Extent Score (VES)</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage repigmentation is assessed through change in score from baseline. Range 0-100. Higher score=greater depigmentation/worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage repigmentation: Photographs</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage repigmentation is assessed through comparison of photographs of vitiligo lesions from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to repigmentation</measure>
    <time_frame>through study treatment completion at 24-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life score from baseline: Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Baseline through week 12 and through study treatment completion at 24-weeks</time_frame>
    <description>Used to assess treatment response on subject's quality of life. Range 0-30. Higher score=larger effect on patient's life/worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life score from baseline: Patient Global Impression of Change (PGIC)</measure>
    <time_frame>Baseline through week 12 and through study treatment completion at 24-weeks</time_frame>
    <description>1-tem questionnaire designed to assess a subject's impression of disease improvement. 7 point Likert scale ranging from &quot;Very much better&quot; to &quot;Very much worse&quot; with &quot;no change&quot; in the middle. Range[1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderately better, 6-better/a definite improvement, 7-a great deal better]. Higher score=better impression of change/better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life score from baseline: Self-Assessment Vitiligo Extent Score (SA-VES)</measure>
    <time_frame>Baseline through week 12 and through study treatment completion at 24-weeks</time_frame>
    <description>Validated patient reported outcome measurement to provide information about disease extent and repigmentation. Range 0-100. Higher score=greater depigmentation/worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>through study treatment completion at 24-weeks</time_frame>
    <description>incidence and nature of any adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Skin and Connective Tissue Diseases</condition>
  <condition>Skin Diseases</condition>
  <condition>Pigmentation Disorder</condition>
  <condition>Hypopigmentation</condition>
  <condition>Biologic</condition>
  <condition>Vitiligo</condition>
  <arm_group>
    <arm_group_label>Vitiligo Patients on Tildrakizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tildrakizumab</intervention_name>
    <description>2 100mg subcutaneous injections Q4W</description>
    <arm_group_label>Vitiligo Patients on Tildrakizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Diagnosis of vitiligo&#xD;
&#xD;
          -  Clinically stable vitiligo: defined as no new vitiligo patches and no enlargement of&#xD;
             existing patches in previous 3 months.&#xD;
&#xD;
          -  Able to provide voluntary, written, informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically active vitiligo: defined as new vitiligo patches or enlargement of existing&#xD;
             patches in previous 3 months&#xD;
&#xD;
          -  Concurrent skin disease in the study area&#xD;
&#xD;
          -  Immunocompromise&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) who are unwilling to practice highly effective&#xD;
             contraception prior to the initial dose/start of the first treatment, during the&#xD;
             study, and for at least 12 weeks after the last dose.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dedee Murrell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New South Wales</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dedee Murrell, MD</last_name>
    <phone>9598 5800</phone>
    <phone_ext>02</phone_ext>
    <email>d.murrell@unsw.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Henry Lee</last_name>
    <email>z5214507@unsw.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Premier Specialists Pty Ltd</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bianca Wills</last_name>
      <email>premierspectrialsbianca@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dedee Murrell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Daniel, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Wittal, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://dermatologytrialsaustralia.com.au/</url>
    <description>Premier Specialists Dermatology</description>
  </link>
  <reference>
    <citation>Jerjen R, Moodley A, Sinclair R. Repigmentation of acrofacial vitiligo with subcutaneous tildrakizumab. Australas J Dermatol. 2020 Nov;61(4):e446-e448. doi: 10.1111/ajd.13346. Epub 2020 May 21.</citation>
    <PMID>32441048</PMID>
  </reference>
  <reference>
    <citation>Vaccaro M, Cannavò SP, Imbesi S, Cristani M, Barbuzza O, Tigano V, Gangemi S. Increased serum levels of interleukin-23 circulating in patients with non-segmental generalized vitiligo. Int J Dermatol. 2015 Jun;54(6):672-4. doi: 10.1111/ijd.12392. Epub 2014 Nov 27.</citation>
    <PMID>25427848</PMID>
  </reference>
  <reference>
    <citation>Hu Y, Qi X, Hu Y, Lu Y, Liu K, Han X, Mao Z, Wu Z, Zhou X. Effects of CO2 fractional laser therapy on peripheral blood cytokines in patients with vitiligo. Dermatol Ther. 2019 Jul;32(4):e12992. doi: 10.1111/dth.12992. Epub 2019 Jun 17.</citation>
    <PMID>31172649</PMID>
  </reference>
  <reference>
    <citation>Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol. 2004 Jun;140(6):677-83.</citation>
    <PMID>15210457</PMID>
  </reference>
  <reference>
    <citation>van Geel N, Lommerts J, Bekkenk M, Wolkerstorfer A, Prinsen CAC, Eleftheriadou V, Taïeb A, Picardo M, Ezzedine K, Speeckaert R. Development and Validation of the Vitiligo Extent Score (VES): an International Collaborative Initiative. J Invest Dermatol. 2016 May;136(5):978-984. doi: 10.1016/j.jid.2015.12.040. Epub 2016 Jan 28.</citation>
    <PMID>26827762</PMID>
  </reference>
  <reference>
    <citation>Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210-6.</citation>
    <PMID>8033378</PMID>
  </reference>
  <reference>
    <citation>van Geel N, Lommerts JE, Bekkenk MW, Prinsen CA, Eleftheriadou V, Taieb A, Picardo M, Ezzedine K, Wolkerstorfer A, Speeckaert R; international Vitiligo Score Working Group. Development and validation of a patient-reported outcome measure in vitiligo: The Self Assessment Vitiligo Extent Score (SA-VES). J Am Acad Dermatol. 2017 Mar;76(3):464-471. doi: 10.1016/j.jaad.2016.09.034. Epub 2016 Nov 22.</citation>
    <PMID>27887798</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 31, 2021</last_update_submitted>
  <last_update_submitted_qc>July 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tildrakizumab</keyword>
  <keyword>non-segmental vitiligo</keyword>
  <keyword>interleukin-23</keyword>
  <keyword>IL-23</keyword>
  <keyword>biological treatment</keyword>
  <keyword>pilot study</keyword>
  <keyword>Anti-Inflammatory Agents</keyword>
  <keyword>Anti-Inflammatory Agents, Non-Steroidal</keyword>
  <keyword>Vitiligo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Connective Tissue Diseases</mesh_term>
    <mesh_term>Pigmentation Disorders</mesh_term>
    <mesh_term>Hypopigmentation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

